The PARP inhibitors were used successfully as monotherapy of BRCA1/2 mutated cancers, based on the fact that PARP inhibitions reduce the rate of DNA repair (Bhattacharjee and Nandi, 2017; Ashworth and Lord, 2018). This evidence concerns the gene PARP1 and cancer.